Bisphosphonates in osteoporosis: Recent clinical experience

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 2, 2000, Pages 225-238

  McClung, Michael R ^a  

^a OREGON OSTEOPOROSIS CENTER   (United States)

Author keywords

Alendmnate; Bisphosphonates; Bone density; Corticosteroid indnced osteoporosis; Etidronate, fractures; Ibandronate; Pamidronate; Postmenopausal osteoporosis; Risedronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ANIMAL; CLINICAL TRIAL; FEMALE; HUMAN; MALE; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

ANIMALS; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0033754938     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.2.225     Document Type: Article

References (63)

1. FLEISCH H: liispbospboimtes in Bunc Disease: from the Laboratory to the Patient. (3rd Edition). Parthenon Publishing. New York, USA (1997). Historical review of the clinical development of bisphosphonates.
2. POKRAS AG, HOLLAND SD, GEKTZUJ : Pharmacokinctics of alendronate. Clin. Pharniacokinet. (1999) 36:315-328.
3. FLEISCH H: Bisphosphonates: mechanisms of action. Endocr. Ker. (1998) 19:80-100. General review of intracellular processes altered by bisphosphonates.
4. RUSSELL RGG, ROGERS MG: Bisphosphonates: from the laboratory to the clinic and back again. Bone (1999) 25:97-106. Review of differences in primary mechanisms of actions of different classes of bisphosphonates.
5. VITTE C, FLEISCH H, GUENTHER HL: Bisphosphonates induce ostcoblasts to secrete an inhibitor of ostcoclast-mediated résorption. Endocrinology' (1996) 137:2324-2333.
6. ADAMI S, ZAMBERLAN N: Adverse effects of bisphosphonates. A comparative review. Drug Self. (1996) 14:158-170. Overview of safety and tolerability of bisphosphonates.
7. LENEHAN TM. IIALLIGAND M, NUNAMAKER DM et al.: Effect of EHDP on fracture healing in dogs. J. Ortbo/i. Res. (1985) 3:499-507.
8. ADAMI S. BHALLA AK, DORIZZI R et ill.: The acute phase response after bisphosphona'tc administration. Ciilcif. Tissue Int. (1987) 41:326-331.
9. MCCLUNG MR, TOU CKP, GOLDSTEIN N et al.: Tiludrojiatc therapy for Paget's disease of bone. Bone (1995) 17:493S-496S.
10. LUFKIN EG, ARGUETA R, WHITAKER MD et cit.: Pamidronate: an unrecognized problem in gastrointestinal tolerabiUty. Osteopoms. Int. (1994) 4:320-322.
11. DEGROEN PC. LUBI3E DF, HIRSCH LJ et ill.: Esophagitis associated with the use of alcndronatc. A'. Eiigl.J. Meet. (1996)335:1016-1021.
12. KIBEIRO A, DEVAULT KR, \VOLFE JT III, STARK ME: Alcndronatc-associatcd esophagitis: endoscopie and pathologic features. Gastrointest. Einlöse. (199S) 47:525-528.
13. BLACK DM, CUMMINGS SR. KARPF DB el ah Randomized trial of effect of alcndronatc on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348:1535-1541. One arm of the major study evaluating effect of alendronate on fracture risk (Fracture Intervention Trial).
14. POLS HAP, FELSENBERG D, HANLEY DA et al.: Multinational, placebo-controlled, randomized trial of the effects of alcndronatc on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteopoms. Int. (1999) 9:461-468.
15. PETER CP, HANDT LK, SMITH SM: Esophageal irritation due to alcndronatc sodium Tablets: possible mechanisms. Digest. Disease Sei. (1998) 43:1998-2002.
16. MACAROL V, FRAUNFELDER FT: Pamidronatc disodium and possible ocular adverse drug reactions. Am. J. Ophtbalmol. (1994) 118:220-224.
17. RECKER RR, HASSING GS, LAU JR et al.: The hyperphosphatcmic effect of disodium ethane-l-hydroxy-1, 1-disphosphonatc (EHDP): renal handling of phosphorous and renal response to parathyroid hormone. J. Lab. Clin. Meel. (1973) 81:258-266.
18. JODRELL DI, IVESON TJ, SMITH IE: Symptomatic hypocalcemia after treatment with high-dose aminohydroxypropylidene diphosphonate. Lancet (1987) 1:622.
19. CHESNUT CH III, MCCLUNG MR, ENSRUD K et a!.: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am. J. Mecl. (1995) 99:144-152.
20. NIEVES , KOMAR L. COSMAN F, LINDSAY R: Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am.J. Clin. AViJ. (199S) 67:18-24.
21. EASTELL R: Treatment of postmenopausal ostcoporosis. A'. Engl.J. Mctl. (1998) 338:736-7-16. Current review of osteoporosis management.
22. HEANEY RI': The bone remodeling transient: implications for the interpretation of clinical studies of bone mass changes..J. Hone Miner. Kcs. (199-i) 9:1515-1523.
23. GARNERO P? HAUSCHERR E. CHAPUY M-C ctal.: Markers of bone résorption predict hip fractures in elderly women: the EP1DOS prospective study. J. Bone Miner. AVi-. (1996) 11:1531-1538.
24. STORM T, THAMSHORG G, STEINICHE T, GENANT HK. SORENSEN OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. A'. Engl.J. Mctl. (1990) 322:1265-1271.
25. WATTS NB, HARMS ST. GENANT HK c/ til.-. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. A'. Engl.J. Mat. (1990) 323:73-79. Major clinical osteoporosis study with etidronate.
26. MILLER I'D, WATTS NI!, LICATA AA et al.-. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after 7 years of treatment. Am.J. Mcft. (1997) 103:468-476.
27. HERD RJ.M, I3ALENA R, BLAKE GM, RYAN PJ. FOGELMAN I: The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am.J. Mal. (1997) 103:92-99.
28. MEUNIER PJ, CONFAVREUX E, TUOINEN J et al.: Prevention for early postmenopausal bone loss with cyclical etidronate therapy: a double-blind, placebo-controlled study and 1-ycar follow-up./ Clin. Endocrinul. Melab. (1997) 82:2784-2791.
29. GARNERO P, SHIH WJ, GINEYTS E, KARPF DB, DELMAS PD: Comparison of new biochemical markers of bone turnover-in late postmenopausal osteoporotic women in response to alcndronatc treatment. J. Clin. Emlocrinol. Mctcib. (1994) 79:1693-1700.
30. STOCK JL. BELL NH, CHESNUT CH III ctal.: Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover arc maintained after discontinuation of alcndronatc in postmenopausal women. Am.J. Mat. (1997) 103:291-297.
31. L1BERMAN UA, \VEISS SR, BROLLJL: Effect of tlirce years treatment with oral alcndronate on fracture incidence in women with postmenopausal osteoporosis. A'. Engl. J. Mcil. (1995) 333:1437-1443. Pivotal Phase III alendronate trial for postmenopausal osteoporosis.
32. TUCCI JR. TONINO RP, EMKEY RD et eil.: Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. A m.J. MetJ. (1996) 101:488-501.
33. DEVOGELAER JP, HROLL H, CORUEA-ROTTER R et ah. Oral alcndronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.Bone 1996; 18:141-150.
34. BONE HG, DOWNS R\V, TUCCIJR et al.: Dose-response relationships for alcndronatc treatment in osteoporotic elderly women. J. Clin. Endocrinol. Mctab. (1997) 82:265-274.
35. SCHNEIDER DL. GREENSPAN SL. MCCLUNG MR et ill.: Alendronate for treatment of osteoporosis in elderly female long-term care facility. Annual Meeting of Tlje Endocrine Society. San Diego, USA (1999).
36. KARPF DI5, SHAI'IRO DR, SEEMAN E et til.: Prevention of nonvcrtcbral fractures by alcndronatc. A mcta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 277:1159-1164.
37. CUMMINGS SR, liLACK DM, THOMPSON D ut ill.: Effect of alendronatc on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA (1998) 280:2077-2082. Other half of the Fracture Intervention Trial with alendronate demonstrating an effect of therapy on reduction of non-spine fractures in women with but not without osteoporosis.
38. ROSS PD, DAV1S JVC', EPSTEIN RS et al.: Pre-existing fractures and bone mass predict vertebral fracture in women. Ann. Intern. Meet. (1991) 114:919-923.
39. HOSKING D, CHILVERS CED, CHRISTIANSEN C et al: Prevention of bone loss with alcndronatc in postmenopausal women uriHcr 60 years of age. Ar. Engl. J. Med. (1998) 338:485-492. Largest osteoporosis prevention study. Compares oestrogen with alendronate therapy.
40. MCCLUNG M, CLEMMESEN B, DAIFOTIS A et al.: Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Ann. Intern. Med. (1998) 128:253-261.
41. EL HAJJ-FULE1HAN G, LUCKEY M, BAUER R et ah Effects of discontinuation of alcndronatc in early postmenopausal women. J. Bone Miner. Kes. (1997) 12:S143.
42. WIMALAVi'ANSA SJ: Combined therapy with estrogen and ctidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am.]. Med. (1995) 99:36-41.
43. GREENSPAN S, BANKHURST A, BELL N el a I.: Effects of alcndronatc and estrogen, alone and in combination, on bone mass and bone turnover in postmenopausal osteoporosis. Bone (199SJ 25(S5):S174.
44. LINDSAY R, COSMAN F, LOBO RA et al.: Addition of alcndronatc to ongoing hormone replacement therapy in the treatment of ostcoporosis: a randomized, controlled clinical trial./ Clin. Endocrinol. Metab. (1999)84:3076-3081.
45. PEKETZ A. BODY JJ, DUMON JC et al.: Cyclical pamidronatc infusions in postmcnopausal osteoporosis. Maturiteis(l996) 25:69-75.
46. MCCLUNG MR, BENSEN W, ISOLOGNESE MA et cil.: Riscdronatc increases HMD at the hip, spine and radius in postmcnopausal women with low bone mass..J. Bone Miner. Kes. (1997) 12:Sl69.
47. HARRIS ST, WATTS NB, GENANT HK et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmcnopausal ostcoporosis. JAIM (1999; 282:13-44-1352. The first major study published evaluating the efficacy of risedronate on fracture risk in women with osteoporosis.
48. EASTELL R. MINNE H, SORENSEN O et al.: Risedronate reduces fracture risk in women with established postmcnopausal ostcoporosis. Ccilcif. Tissue Int. (1999) 64:543.
49. MILLER P, ROUX C, MCCLUNG M el cit.: KLsedronale reduces hip fractures in patients with low femoral neck bone mineral density. Tl.te American College of Rheumatology- Boston, USA (1999). Preliminary results of the first study specifically designed to evaluate the effects of bisphosphonate therapy on hip fracture risk.
50. MCCLUNG M, EASTELL R, VC'ATTS N et al.: Risedronate is wcll-tolcratcd in women with postmcnopausal osteoporosis. 21st Annual Meeting of the American Society for Bone ana" Mineral Society. St. Louis, USA (1999).
51. RAVN P, CLEMMESON B, RIIS BJ etal.: The effect on bone mass and bone markers of different doses of ibandronatc: a new bisphosphonate for prevention and treatment of postmcnopausal ostcoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-ranging study. Boue (1996) 19:527-533.
52. THIEBAUD D, BURCKHAKDT P, KRIEGBAUM H et al.: Three monthly intravenous injections of ibandronatc in the treatment of postmenopausal osteoporosis. Am. J. Meet. (1997) 103:298-307.
53. LANE NE. LUKERT B: The science and therapy of glucocorticoid-induced bone loss. Enclocrin. MeUib. Clinics X. Am. (1998) 27:465-483. Recent overview of pathophysiology and treatment of corticosteroid-induced bone disease.
54. ADACHI JD, BENSEN \VG. BROWN J et dl.: Intermittent ctidronate therapy to prevent corticosteroid-induced osteoporosis. Ar. Engl.J. Mctl. (1997) 337:382-387. Major randomised clinical trial of etidronate in patients receiving corticosteroids.
55. SAAG KG. E.MKEY R, SCHNITZER TJ et cil,-. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. A'. Engl. J. Meet. (1998) 339:292-299. Major randomised clinical trial of âlendronate in patients on steroid therapy.
56. ORVi'OLL ES, KLEIN RF: Osteoporosis in men. Emlocr. KM: (1995) 16:87-116. Comprehensive review of palhophysiology and epidemiology of male osteoporosis.
57. GEUSENSP, VANHOOFJ, RAUSJEFc/nJ.: Treatment with ctidronate for men with idiopathic osteoporosis. Ann. Rheum. Dis. (1997) 56:280.
58. ORVi'OLL ES: Alendronate treatment of osteoporosis in men./ Bom-Miner. Key. (1999) 14:S184.
59. GLORIEUX FH, BISHOP NJ, PLOTKIN H et al.: Cyclic administration of pamidronatc in children with severe ostcogencsis imperfccta. A'. Engl.J. Med. (1998) 33:947-952.
60. ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmcnopausal women with osteoporosis treated with raloxifcne: results from a 3-year randomized clinical trial. JAMA (1999) 282:637-645.
61. MCCLU.N'G MR: Therapy for fracture prevention. JAMA (1999) 282:687-689.
62. KANIS JA. DELMAS PD, BUlTCKHARDT P et al. Guidelines for the diagnosis and management of osteoporosis. Osteopoivs. Int. (1997) 7:390-406.
63. Guidelines of International Osteoporosis Foundation. National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis. Excerpta Medica, Belle Meade, NJ, USA (1998).